Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology
Immune checkpoint blockade (ICB) has gained unparalleled success in the treatment of colorectal cancer (CRC). However, undesired side effects, unsatisfactory response rates, tumor metastasis, and drug resistance still hinder the further application of ICB therapy against CRC. Advancing ICB with nano...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-10-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1027124/full |
| _version_ | 1797985778651889664 |
|---|---|
| author | Zefan Liu Yucheng Xiang Yaxian Zheng Xin Kang |
| author_facet | Zefan Liu Yucheng Xiang Yaxian Zheng Xin Kang |
| author_sort | Zefan Liu |
| collection | DOAJ |
| description | Immune checkpoint blockade (ICB) has gained unparalleled success in the treatment of colorectal cancer (CRC). However, undesired side effects, unsatisfactory response rates, tumor metastasis, and drug resistance still hinder the further application of ICB therapy against CRC. Advancing ICB with nanotechnology can be game-changing. With the development of immuno-oncology and nanomaterials, various nanoplatforms have been fabricated to enhance the efficacy of ICB in CRC treatment. Herein, this review systematically summarizes these recent nano-strategies according to their mechanisms. Despite their diverse and complex designs, these nanoplatforms have four main mechanisms in enhancing ICB: 1) targeting immune checkpoint inhibitors (ICIs) to tumor foci, 2) increasing tumor immunogenicity, 3) remodeling tumor microenvironment, and 4) pre-sensitizing immune systems. Importantly, advantages of nanotechnology in CRC, such as innovating the mode-of-actions of ICB, modulating intestinal microbiome, and integrating the whole process of antigen presentation, are highlighted in this review. In general, this review describes the latest applications of nanotechnology for CRC immunotherapy, and may shed light on the future design of ICB platforms. |
| first_indexed | 2024-04-11T07:23:29Z |
| format | Article |
| id | doaj.art-a635620e4e1a431ea4d76815d21d0673 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T07:23:29Z |
| publishDate | 2022-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-a635620e4e1a431ea4d76815d21d06732022-12-22T04:37:09ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-10-011310.3389/fimmu.2022.10271241027124Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnologyZefan Liu0Yucheng Xiang1Yaxian Zheng2Xin Kang3Department of General Surgery, First People's Hospital of Shuangliu District, Chengdu, ChinaDepartment of General Surgery, First People's Hospital of Shuangliu District, Chengdu, ChinaDepartment of Pharmacy, Third People’s Hospital of Chengdu, Chengdu, ChinaDepartment of General Surgery, First People's Hospital of Shuangliu District, Chengdu, ChinaImmune checkpoint blockade (ICB) has gained unparalleled success in the treatment of colorectal cancer (CRC). However, undesired side effects, unsatisfactory response rates, tumor metastasis, and drug resistance still hinder the further application of ICB therapy against CRC. Advancing ICB with nanotechnology can be game-changing. With the development of immuno-oncology and nanomaterials, various nanoplatforms have been fabricated to enhance the efficacy of ICB in CRC treatment. Herein, this review systematically summarizes these recent nano-strategies according to their mechanisms. Despite their diverse and complex designs, these nanoplatforms have four main mechanisms in enhancing ICB: 1) targeting immune checkpoint inhibitors (ICIs) to tumor foci, 2) increasing tumor immunogenicity, 3) remodeling tumor microenvironment, and 4) pre-sensitizing immune systems. Importantly, advantages of nanotechnology in CRC, such as innovating the mode-of-actions of ICB, modulating intestinal microbiome, and integrating the whole process of antigen presentation, are highlighted in this review. In general, this review describes the latest applications of nanotechnology for CRC immunotherapy, and may shed light on the future design of ICB platforms.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1027124/fullcolorectal cancerimmune checkpoint inhibitorsnanotechnologydrug deliverytumor microenvironment |
| spellingShingle | Zefan Liu Yucheng Xiang Yaxian Zheng Xin Kang Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology Frontiers in Immunology colorectal cancer immune checkpoint inhibitors nanotechnology drug delivery tumor microenvironment |
| title | Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology |
| title_full | Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology |
| title_fullStr | Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology |
| title_full_unstemmed | Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology |
| title_short | Advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology |
| title_sort | advancing immune checkpoint blockade in colorectal cancer therapy with nanotechnology |
| topic | colorectal cancer immune checkpoint inhibitors nanotechnology drug delivery tumor microenvironment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1027124/full |
| work_keys_str_mv | AT zefanliu advancingimmunecheckpointblockadeincolorectalcancertherapywithnanotechnology AT yuchengxiang advancingimmunecheckpointblockadeincolorectalcancertherapywithnanotechnology AT yaxianzheng advancingimmunecheckpointblockadeincolorectalcancertherapywithnanotechnology AT xinkang advancingimmunecheckpointblockadeincolorectalcancertherapywithnanotechnology |